Crucial Conversations on the Future of Global Health!
Thought-provoking, worldwide issues will be deconstructed by acclaimed panelists representing multiple stakeholders from around the world in this growing ecosystem of life sciences. DIAmonds represent rare opportunities to listen to open conversations on controversial topics such as innovation in global health and international regulatory collaboration.
Monday, June 15
R&D Leader Perspectives: Innovative Efforts Transforming Drug Development8:00-10:00AM
Part of the Opening Plenary and KeynoteModerator: DIA Representative
This exciting and thought-provoking session will feature a panel of leaders at the top of their field, discussing emerging forces that are shaping the global future of healthcare and innovative ideas that are transforming drug development. Ranging from evolving basic science to the sharing of granular, consumable, and high-quality data from multiple sources, to emerging disruptive technology, to accelerating regulatory review and approval, a host of innovations will be touched upon. The panel will also discuss the clear power of collaborative partnerships in drug development that are involving multiple stakeholders, including patients.
Dalvir Gill, PhD, CEO, TransCelerate
Michelle Rohrer, PhD, Senior Vice President, Global Head of Product Development Regulatory and Policy, Roche
Rod MacKenzie, PhD, Executive Vice President, Chief Development Officer, Pfizer Inc
Christopher Austin, MD, Director, National Institutes of Health; National Center for Advancing Translational Sciences
Additional panelists to be announced.
Thursday, June 18
Keeping Up with FDA and EMA Collaborations: Question Time9:00-10:15AM
Session Co-Chairs: Sandra Kweder, DrMed, MD, Deputy Director, Liaison to the EMA, Office of International Programs, OC, FDA, and Tânia Teixeira, PharmD, EMA Liaison Official at FDA, European Medicines Agency (EMA), European Union
How do large regulatory agencies collaborate? What are the challenges they face, in organizations with different structures and working under different legislative frameworks, in finding ways to align to facilitate and enhance global medicines development? This forum brings together pairs of experts from FDA and EMA to launch discussion in such context, with focus on several themes that will provide a foundation for discussing challenges and successes in communication and collaboration covering four areas.
Panelists to be announced.
FDA Town Hall10:45AM-12:00PM
Session Chair: DIA Representative
This forum will include discussions and updates from FDA leadership on regulatory issues and the audience will be invited to submit questions of general interest.
Panelists to be announced.